Medchemexpress LLC PROTAC degrader targeting Bruton's tyrosine kinase (BTK) | 2416131-46-7 | 99.7% | 719.83 | C39H45N9O5 | 10 MG

Supplier:  Medchemexpress LLC HY15322010MG

NX-2127 is an orally bioavailable PROTAC degrader that targets Bruton's tyrosine kinase (BTK). It induces proteasomal degradation of BTK, shows activity against BTK C481S resistance mutants, degrades IKZF1 and IKZF3 transcription factors, and has demonstrated cellular and in vivo preclinical activity while promoting T cell activation and IL-2 production.

• Orally bioavailable PROTAC degrader of BTK.
• Induces proteasomal degradation of BTK and reduces BTK signaling.
• Active against BTK C481S resistance mutants in cellular models.
• Degrades IKZF1 and IKZF3, providing immunomodulatory effects.
• Stimulates T cell activation and increases IL-2 production in primary human T cells.
• Demonstrated efficacy in preclinical in vivo models.

Catalog No. 50-002-86208